Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 373

The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.

Thrombotic Microangiopathy and the Kidney

Open access
Brocklebank, Vicky, Wood, Katrina M., Kavanagh, David·2018·Clinical Journal of the American Society of Nephrology
DOI 10.2215/cjn.00620117
Open this paper in CoChat — free account

Abstract

Thrombotic microangiopathy can manifest in a diverse range of diseases and is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and organ injury, including AKI. It can be associated with significant morbidity and mortality, but a systematic approach to investigation and prompt initiation of supportive management and, in some cases, effective specific treatment can result in good outcomes. This review considers the classification, pathology, epidemiology, characteristics, and pathogenesis of the thrombotic microangiopathies, and outlines a pragmatic approach to diagnosis and management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2215/cjn.00620117

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 96 references

Research works printed but not linked: 34

  1. Barrera-Vargas, 2016, Renal thrombotic microangiopathy in proliferative lupus nephritis: Risk factors and clinical outcomes: A Case-Control study, J Clin Rheumatol, 22, 235, 10.1097/RHU.0000000000000425 · doi:10.1097/rhu.0000000000000425
  2. Saland, 2014, Liver-kidney transplantation to cure atypical HUS: Still an option post-eculizumab?, Pediatr Nephrol, 29, 329, 10.1007/s00467-013-2722-2 · doi:10.1007/s00467-013-2722-2
  3. Brocklebank, Factor H: Autoantibody associated atypical haemolytic uraemic syndrome in children in the United Kingdom and Ireland [published online ahead of print July 24, 2017], Kidney Int
  4. Nishijima, 2013, Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin, Intern Med, 52, 1111, 10.2169/internalmedicine.52.9180 · doi:10.2169/internalmedicine.52.9180
  5. Alashkar, 2017, Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab, Ann Hematol, 96, 589, 10.1007/s00277-017-2924-y · doi:10.1007/s00277-017-2924-y
  6. Cullinan, 2015, Case report: Benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome, Pediatrics, 135, e1506, 10.1542/peds.2014-3503 · doi:10.1542/peds.2014-3503
  7. George, 2003, The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, Curr Opin Hematol, 10, 339, 10.1097/00062752-200309000-00003 · doi:10.1097/00062752-200309000-00003
  8. Scully, 2011, A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura, Blood, 118, 1746, 10.1182/blood-2011-03-341131 · doi:10.1182/blood-2011-03-341131
  9. Clark, 2015, A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab, Br J Haematol, 170, 208, 10.1111/bjh.13408 · doi:10.1111/bjh.13408
  10. Westland, 2014, Phenotypic expansion of DGKE-associated diseases, J Am Soc Nephrol, 25, 1408, 10.1681/ASN.2013080886 · doi:10.1681/asn.2013080886
  11. Hughes, 2002, Molecular basis for high renal cell sensitivity to the cytotoxic effects of shigatoxin-1: Upregulation of globotriaosylceramide expression, J Am Soc Nephrol, 13, 2239, 10.1097/01.ASN.0000027873.85792.52 · doi:10.1097/01.asn.0000027873.85792.52
  12. Spinale, 2013, Long-term outcomes of Shiga toxin hemolytic uremic syndrome, Pediatr Nephrol, 28, 2097, 10.1007/s00467-012-2383-6 · doi:10.1007/s00467-012-2383-6
  13. Spinale, 2013, Update on Streptococcus pneumoniae associated hemolytic uremic syndrome, Curr Opin Pediatr, 25, 203, 10.1097/MOP.0b013e32835d7f2c · doi:10.1097/mop.0b013e32835d7f2c
  14. Alpers, 2003, Light at the end of the TUNEL: HIV-associated thrombotic microangiopathy, Kidney Int, 63, 385, 10.1046/j.1523-1755.2003.00743.x · doi:10.1046/j.1523-1755.2003.00743.x
  15. Peraldi, 1999, Acute renal failure in the course of HIV infection: A single-institution retrospective study of ninety-two patients and sixty renal biopsies, Nephrol Dial Transplant, 14, 1578, 10.1093/ndt/14.6.1578 · doi:10.1093/ndt/14.6.1578
  16. Becker, 2004, HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: An observational study, Clin Infect Dis, 39, S267, 10.1086/422363 · doi:10.1086/422363
  17. Gottschall, 1991, Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: A new clinical entity, Blood, 77, 306, 10.1182/blood.V77.2.306.306 · doi:10.1182/blood.v77.2.306.306
  18. Bennett, 2013, Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: A report from the Southern Network on Adverse Reactions (SONAR), Br J Haematol, 161, 896, 10.1111/bjh.12303 · doi:10.1111/bjh.12303
  19. Verbiest, 2014, De novo thrombotic microangiopathy after non-renal solid organ transplantation, Blood Rev, 28, 269, 10.1016/j.blre.2014.09.001 · doi:10.1016/j.blre.2014.09.001
  20. Ponticelli, 2006, Thrombotic microangiopathy after kidney transplantation, Transpl Int, 19, 789, 10.1111/j.1432-2277.2006.00354.x · doi:10.1111/j.1432-2277.2006.00354.x
  21. Zuber, 2013, Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation, Transplant Rev (Orlando), 27, 117, 10.1016/j.trre.2013.07.003 · doi:10.1016/j.trre.2013.07.003
  22. Dhakal, 2017, Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?, Bone Marrow Transplant, 52, 352, 10.1038/bmt.2016.253 · doi:10.1038/bmt.2016.253
  23. Shavit, 2010, Severe renal failure and microangiopathic hemolysis induced by malignant hypertension--case series and review of literature, Clin Nephrol, 73, 147, 10.5414/CNP73147 · doi:10.5414/cnp73147
  24. George, 2011, Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia, Oncology (Williston Park), 25, 908
  25. Lesesne, 1989, Cancer-associated hemolytic-uremic syndrome: Analysis of 85 cases from a national registry, J Clin Oncol, 7, 781, 10.1200/JCO.1989.7.6.781 · doi:10.1200/jco.1989.7.6.781
  26. Cooper, 2004, Familial mesangio-capillary glomerulonephritis with initial presentation as haemolytic uraemic syndrome, Nephrol Dial Transplant, 19, 230, 10.1093/ndt/gfg470 · doi:10.1093/ndt/gfg470
  27. Woodworth, 2016, Scleroderma renal crisis and renal involvement in systemic sclerosis, Nat Rev Nephrol, 12, 678, 10.1038/nrneph.2016.124 · doi:10.1038/nrneph.2016.124
  28. Fakhouri, Haemolytic uraemic syndrome [published online ahead of print February 25, 2017], Lancet
  29. Waters, 2007, Hemolytic uremic syndrome associated with invasive pneumococcal disease: The United kingdom experience, J Pediatr, 151, 140, 10.1016/j.jpeds.2007.03.055 · doi:10.1016/j.jpeds.2007.03.055
  30. Cochran, 2004, Pneumococcus-induced T-antigen activation in hemolytic uremic syndrome and anemia, Pediatr Nephrol, 19, 317, 10.1007/s00467-003-1382-z · doi:10.1007/s00467-003-1382-z
  31. Prestidge, 2009, Ten years of pneumococcal-associated haemolytic uraemic syndrome in New Zealand children, J Paediatr Child Health, 45, 731, 10.1111/j.1440-1754.2009.01603.x · doi:10.1111/j.1440-1754.2009.01603.x
  32. van den Born, 2007, The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension, Am J Hypertens, 20, 900, 10.1016/j.amjhyper.2007.02.018 · doi:10.1016/j.amjhyper.2007.02.018
  33. Akimoto, 2011, Clinical features of malignant hypertension with thrombotic microangiopathy, Clin Exp Hypertens, 33, 77, 10.3109/10641963.2010.503303 · doi:10.3109/10641963.2010.503303
  34. Ghossein, 2016, Recent developments in the classification, evaluation, pathophysiology, and management of scleroderma renal crisis, Curr Rheumatol Rep, 18, 5, 10.1007/s11926-015-0551-y · doi:10.1007/s11926-015-0551-y

Cited by

See all 373

Metadata

Authors
Brocklebank, V., Wood, K. M., & Kavanagh, D.
Venue
Clinical Journal of the American Society of Nephrology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2017-10-17
Volume
13
Issue
2
Pages
300-317
ISSN
  • 1555-9041 (ISSN-L)
  • 1555-905X
DOI
10.2215/cjn.00620117
OpenAlex
W2765086424
Cited by
373
References
96
FWCI
8.90
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Thrombotic Microangiopathy and the Kidney. https://app.cochat.ai/papers/10.2215/cjn.00620117
The paper
Brocklebank, V., Wood, K. M., & Kavanagh, D. (2018). Thrombotic Microangiopathy and the Kidney. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.00620117

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.